Focus: Galt Pharmaceuticals is a diagnostics and specialty pharmaceuticals company headquartered in Atlanta with a portfolio centered on musculoskeletal and neurology indications. The company operates a lean commercial model focused on branded generics and established pharmaceutical products.
Profile data last refreshed 49m ago · AI intelligence enriched 2w ago
Hot — 66 jobs added in 30d
Net +51 (66 new, 15 removed). Aggressive expansion phase.
Galt is a commercial-execution play with fortress-like revenue concentration—suitable for experienced sales leaders seeking stability, but high-risk for those prioritizing innovation, pipeline depth, or long-term career mobility.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Core revenue generator (100% of company revenue) but post-exclusivity with minimal Part D utilization, indicating mature market saturation.
Help build intelligence for Galt Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Galt Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Patent cliff imminent in 2028; benzodiazepine class faces regulatory scrutiny and declining prescribing trends, limiting upside.
Legacy branded generic with no Part D spending data; likely minimal market share behind ORPHENGESIC FORTE.
Buccal tablet antifungal with approaching LOE; niche indication with limited revenue contribution and declining exclusivity protection.
1 discontinued, 1 duplicate formulations not shown
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles